Email mikeherdman.insight@gmail.com

Mike has worked in the field of health technology assessment and outcomes research for over 25 years. He currently runs his own consulting and research company in Barcelona and is Head of Health Outcomes Research at the Office of Health Economics in London. His main areas of interest are the development, validation, application, and interpretation of patient reported outcome (PRO) measures. He has been a member of the EuroQol Group for 25 years, is Chair of the Group’s Younger Populations Working Group, and currently serves on the EuroQol Group’s Executive Committee. Mike has published over 150 peer reviewed articles and book chapters. He loves rock-climbing and jazz.

• NUS Saw Swee Hock School of Public Health
• Head of Health Outcomes Research, Office of Health Economics, London
• Director, Insight Consulting & Research, Barcelona

• Patient Reported Outcomes

• MSc in Bioethics and Law, University of Barcelona, Spain. 1996-1998
• BSc Philosophy (Honors), University of Hull, Humberside, England. 1981-1985

• 2013 – present Head of Health Outcomes, Office of Health Economics
• 2008 – present Director, Insight Consulting & Research
• 2006 – 2010 Researcher, Health Services Research Unit, Institut Municipal d’Investigació Mèdica, Barcelona, Spain
• 2001 –2006 Managing Director, 3D Health Research, Barcelona, Spain
• 1999 – 2002 Researcher, Catalan Agency for Health Technology Assessment and Research, Barcelona.
• 1995 – 1999 Research fellow, Catalan Institute of Public Health, Barcelona

• I frequently provide consulting services to pharmaceutical and medical device companies, as well as to public organisations such as the Catalan Health Quality and Assessment Agency

• Herdman M, Fox-Rushby J, Badia X. A model of equivalence in the cultural adaptation of HRQoL instruments: the universalist approach. Quality of Life Research 1998;4:323-35.
• Herdman M, Rajmil L, Ravens-Sieberer U, Bullinger M, Power M, Alonso J. Expert consensus in the development of a European health-related quality of life measure for children and adolescents: a Delphi study. Acta Paediatrica 2002;91:1385-90.
• Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research 2011;20:1727-36.
• Herdman M, Cole A, Hoyle CK, Coles V, Carroll S, Devlin N. Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. Value in Health 2016;19:255-66.
• Herdman M, Hoyle CK, Coles V, Carroll S, Devlin N. Assessing Patient-Reported Outcomes in Pediatric Populations With Vaccine-Preventable Infectious Diseases: A Systematic Review of the Literature (the PROCHID Study). Value in Health 2016;19:109-19.
• Herdman M, Kerr C, Pavesi M, et al. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L. Journal of Patient Reported Outcomes 2020;4(1):22.